Gene Therapy Finds a Fertile Home in Ohio

The midwestern state has quietly laid the groundwork for a biotech hub.

Written byShawna Williams
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

ABOVE: Sarepta research associate Kaitlin Adegboye stains muscle cryosections for analysis.
© SAREPTA THERAPEUTICS

Sarepta Therapeutics’s outpost in Ohio occupies a collection of offices and labs on the second floor of a large, squat structure known as “Building 4” in a business park outside of Columbus. Despite the facility’s unassuming exterior, the start of research onsite here in spring 2019 marked a milestone in Ohio’s two-decade-long march toward becoming a gene therapy hub. “We’re making a very significant commitment and investment in Columbus,” Doug Ingram, the CEO of Cambridge, Massachusetts–based Sarepta, told Columbus Business First in an article about the new division. “There is a real chance Columbus, Ohio, could become the most important place in the world for gene therapy development.”

We’ve helped prove the concept that gene therapy can actually go from bench to bedside.

With its Ohio research center, Sarepta joins a local gene therapy ecosystem. Bolstered by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor’s degree in biochemistry from Colorado College and a graduate certificate in science communication from the University of California, Santa Cruz. Previously, she worked as a freelance editor and writer, and in the communications offices of several academic research institutions. As news director, Shawna assigned and edited news, opinion, and in-depth feature articles for the website on all aspects of the life sciences. She is based in central Washington State, and is a member of the Northwest Science Writers Association and the National Association of Science Writers.

    View Full Profile

Published In

January/February 2020

A Light in the Dark

Unpacking the Complex Neurobiology of Suicide

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies